REGENXBIO CMO’s 10b5‑1 Sale: Insider Trims Holdings Amid Bull‑Run, Not a Bearish Signal

Insider Selling in a Bull Market: What REGENXBIO’s CMO is Doing and Why It Matters

In the past week, Steve Pa­kola, REGENXBIO’s Chief Medical Officer, sold 5,124 shares of the company’s common stock on a 10b5‑1 plan. The trade, executed at $10.35 per share, reduced his holdings to 247,926 shares. The transaction is noteworthy not because of the price—$10.35 is only 0.4 % below the current market price of $9.38—but because it occurs during a period of strong momentum for the stock, which has climbed 4.13 % in the last week, 2.6 % in the month, and 35 % over the year.

Insider Activity Amid Rising Fundamentals

Pa­kola’s sale joins a wave of insider selling that began in early January. He has sold shares on multiple dates—Feb 1, Jan 6, and Mar 10—while also buying significant amounts earlier in the year, most notably 65,847 shares and 35,402 options on Jan 6. This pattern is common among executives who use 10b5‑1 plans to hedge personal liquidity needs or to diversify portfolios without signaling a lack of confidence. Nonetheless, the timing—just days after the company announced positive interim data from its RGX‑202 trial and ahead of the anticipated Q2 pivotal results—has drawn attention from analysts and retail investors alike.

Implications for Investors

The volume of Pa­kola’s trades is modest relative to the company’s market cap of roughly $518 million. Even a 5,000‑share sale represents less than 0.1 % of outstanding shares, so the direct price impact is minimal. However, insider activity can be interpreted as a sentiment gauge. Pa­kola’s consistent buying early in the year, followed by a series of controlled sales, suggests a strategy of gradual liquidity realization rather than a reaction to any adverse corporate news. For investors, this pattern may reinforce a “buy the dip” thesis: the company’s fundamentals—positive clinical data, a clear regulatory roadmap, and a growing market for gene therapies—appear stronger than any short‑term share price movements.

Profile of Steve Pa­kola

Pa­kola has been with REGENXBIO since its IPO in 2015 and has overseen the development of the RGX‑202 gene therapy. His insider transaction history shows a balanced approach: significant purchases in January, a large option grant later that month, and regular sales via a rule‑based plan. He is the only executive among the company’s top officers to have sold shares in both the first and second quarters of 2026. Unlike other insiders who have sold large blocks (e.g., Kenneth Mills sold 225,000 shares on Jan 27), Pa­kola’s trades are relatively small and spread out, reducing the likelihood of triggering market rumors. His disciplined use of a 10b5‑1 plan indicates an intention to comply with regulatory requirements while maintaining personal financial flexibility.

What This Means for REGENXBIO’s Future

With the FDA expected to review pivotal data in Q2, the company’s valuation is poised for a significant uptick if the trial results hold up. Pa­kola’s controlled selling does not signal a bearish view; instead, it reflects standard corporate governance practices. For investors, the key takeaway is that insider activity should be considered within the broader context of the company’s clinical milestones, market opportunity, and regulatory pathway. If the forthcoming data confirm the safety and efficacy trends observed in the Phase I/II study, REGENXBIO could see a sharp rally, and the modest insider sales are unlikely to dampen that upside.